Bicara Therapeutics Inc. (BCAX) compared with its closest peers (PYXS, CBIO, FHTX, COGT, PRLD). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Pyxis Oncology: named a competitor in the 10-K.
| Company | Market Cap | P/E |
|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | $266.49M | — |
| Crescent Biopharma, Inc. (CBIO) | $717.99M | — |
| Foghorn Therapeutics Inc. (FHTX) | $261.30M | — |
| Cogent Biosciences, Inc. (COGT) | $5.80B | — |
| Prelude Therapeutics Incorporated (PRLD) | $366.30M | — |
| Geron Corporation (GERN) | $864.13M | — |
| Alumis Inc. (ALMS) | $1.17B | — |
| Veru Inc. (VERU) | $39.40M | — |
| Olema Pharmaceuticals, Inc. (OLMA) | $787.48M | — |
| Oruka Therapeutics, Inc. (ORKA) | $6.12B | — |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
BCAX overview · BCAX earnings · BCAX financials · BCAX KPIs · BCAX documents · BCAX ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.